Mirogabalin is an investigational drug.
There have been 9 clinical trials for Mirogabalin.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 27th 2014.
The most common disease conditions in clinical trials are Neuralgia, Myofascial Pain Syndromes, and Fibromyalgia. The leading clinical trial sponsors are Daiichi Sankyo Co., Ltd., Daiichi Sankyo Inc., and Daiichi Sankyo, Inc.
There are ten US patents protecting this investigational drug and one hundred and fifty-two international patents.